rifampin and osimertinib

rifampin has been researched along with osimertinib* in 1 studies

Other Studies

1 other study(ies) available for rifampin and osimertinib

Article	Year
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. CPT: pharmacometrics & systems pharmacology, 2018, Volume: 7, Issue:5 Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. In vitro metabolism data suggested osimertinib is a substrate of cytochrome P450 (CYP)3A4/5, a weak inducer of CYP3A, and an inhibitor of breast cancer resistance protein (BCRP). A combination of in vitro data, clinical pharmacokinetic data, and drug-drug interaction (DDI) data of osimertinib in oncology patients were used to develop the physiologically based pharmacokinetic (PBPK) model and verify the DDI data of osimertinib. The model predicted the observed monotherapy concentration profile of osimertinib within 1.1-fold, and showed good predictability (within 1.7-fold) to the observed peak plasma concentration (C Topics: Acrylamides; Aniline Compounds; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Drug Interactions; Humans; Itraconazole; Models, Theoretical; Neoplasms; Rifampin; Rosuvastatin Calcium; Simvastatin	2018

Article

Year

Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.

CPT: pharmacometrics & systems pharmacology, 2018, Volume: 7, Issue:5

Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. In vitro metabolism data suggested osimertinib is a substrate of cytochrome P450 (CYP)3A4/5, a weak inducer of CYP3A, and an inhibitor of breast cancer resistance protein (BCRP). A combination of in vitro data, clinical pharmacokinetic data, and drug-drug interaction (DDI) data of osimertinib in oncology patients were used to develop the physiologically based pharmacokinetic (PBPK) model and verify the DDI data of osimertinib. The model predicted the observed monotherapy concentration profile of osimertinib within 1.1-fold, and showed good predictability (within 1.7-fold) to the observed peak plasma concentration (C

Topics: Acrylamides; Aniline Compounds; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Drug Interactions; Humans; Itraconazole; Models, Theoretical; Neoplasms; Rifampin; Rosuvastatin Calcium; Simvastatin

2018